Top

Published in:

01-03-2020 | Ureterorenoscopy | Original Article

Tumour architecture, grade and location remain predictors of non-organ-confined upper tract urothelial carcinoma at time of radical nephroureterectomy: results from a multicenter Norwegian external validation study

Authors: Bjarte Almås, Stein Øverby, Ole J. Halvorsen, Lars A. R. Reisæter, Jørg Assmus, Birgitte Carlsen, Anders Loe, Christian Beisland

Published in: World Journal of Urology | Issue 3/2020

Abstract

Purpose

Selecting patients for intensified treatment for upper tract urothelial carcinoma can be challenging, partly due to the lack of accurate preoperative staging tools. Several preoperative staging models for upper tract urothelial carcinoma have been presented, but none have been externally validated. The aim of the current study was to perform an external validation of the Margulis nomogram for predicting non-organ-confined upper tract urothelial carcinoma at time of nephroureterectomy.

Methods

209 patients from two high-volume centres in Norway were treated with radical nephroureterectomy during the period 2005–2017. 163 patients with complete data necessary for external validation of the Margulis nomogram were included in the study. All relevant covariates were analysed with uni- and multivariate regression analysis to assess their ability to predict non-organ-confined disease. The Margulis nomogram was applied on the present cohort to calculate predicted risk of non-organ-confined disease. This was compared to the observed risk to assess model calibration. The Margulis nomogram accuracy was measured as the area under the curve in a receiver operator characteristics curve to evaluate model discrimination.

Results

Tumour grade (OR 28.1, p = 0.001) and architecture (OR 4.72, p < 0.001) were independent predictors of non-organ-confined disease. There was a high concordance between predicted and observed risk quantified with a Cronbach alpha of 0.96. The Margulis nomogram had an area under the curve of 0.83 in predicting non-organ-confined disease when applied on the current cohort.

Conclusions

We consider the Margulis nomogram validated for clinical use.

Available only for authorised users

Larsen IK (2017) Cancer in Norway 2017—cancer incidence, mortality, survival and prevalence in Norway. Norwegian Cancer registry, Oslo, pp 40–42

Stewart GD, Bariol SV, Grigor KM, Tolley DA, McNeill SA (2005) A comparison of the pathology of transitional cell carcinoma of the bladder and upper urinary tract. BJU Int 95:791–793CrossRef

Roupret M, Babjuk M, Comperat E et al (2018) European association of urology guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur Urol 73:111–122CrossRef

Margulis V, Shariat SF, Matin SF et al (2009) Outcomes of radical nephroureterectomy: a series from the upper tract urothelial carcinoma collaboration. Cancer 115:1224–1233CrossRef

Abouassaly R, Alibhai SM, Shah N, Timilshina N, Fleshner N, Finelli A (2010) Troubling outcomes from population-level analysis of surgery for upper tract urothelial carcinoma. Urology 76:895–901CrossRef

Seisen T, Krasnow RE, Bellmunt J et al (2017) Effectiveness of adjuvant chemotherapy after radical nephroureterectomy for locally advanced and/or positive regional lymph node upper tract urothelial carcinoma. J Clin Oncol 35:852–860CrossRef

Fujita K, Taneishi K, Inamoto T et al (2017) Adjuvant chemotherapy improves survival of patients with high-risk upper urinary tract urothelial carcinoma: a propensity score-matched analysis. BMC Urol 17:110CrossRef

Birtle AJ, Chester JD, Jones RJ et al (2018) Results of POUT: a phase III randomised trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC). J Clin Oncol 36:407CrossRef

Leow JJ, Martin-Doyle W, Fay AP, Choueiri TK, Chang SL, Bellmunt J (2014) A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. Eur Urol 66:529–541CrossRef

10.

Matin SF, Margulis V, Kamat A et al (2010) Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer 116:3127–3134CrossRef

11.

Seisen T, Shariat SF, Cussenot O et al (2017) Contemporary role of lymph node dissection at the time of radical nephroureterectomy for upper tract urothelial carcinoma. World J Urol 35:535–548CrossRef

12.

Kondo T, Takagi T, Tanabe K (2015) Therapeutic role of template-based lymphadenectomy in urothelial carcinoma of the upper urinary tract. World J Clin Oncol 6:237–251CrossRef

13.

Roscigno M, Brausi M, Heidenreich A et al (2011) Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer. Eur Urol 60:776–783CrossRef

14.

Inokuchi J, Kuroiwa K, Kakehi Y et al (2017) Role of lymph node dissection during radical nephroureterectomy for upper urinary tract urothelial cancer: multi-institutional large retrospective study JCOG1110A. World J Urol 35:1737–1744CrossRef

15.

Favaretto RL, Shariat SF, Savage C et al (2012) Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma. BJU Int 109:77–82CrossRef

16.

Brien JC, Shariat SF, Herman MP et al (2010) Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. J Urol 184:69–73CrossRef

17.

Margulis V, Youssef RF, Karakiewicz PI et al (2010) Preoperative multivariable prognostic model for prediction of nonorgan confined urothelial carcinoma of the upper urinary tract. J Urol 184:453–458CrossRef

18.

Chen XP, Xiong GY, Li XS et al (2013) Predictive factors for worse pathological outcomes of upper tract urothelial carcinoma: experience from a nationwide high-volume centre in China. BJU Int 112:917–924PubMed

19.

Royston P, Altman DG (2013) External validation of a Cox prognostic model: principles and methods. BMC Med Res Methodol 13:33CrossRef

20.

Fritsche HM, Novara G, Burger M et al (2012) Macroscopic sessile tumor architecture is a pathologic feature of biologically aggressive upper tract urothelial carcinoma. Urol Oncol 30:666–672CrossRef

21.

Eble JN, Sauter G, Epstein JI (2004) Pathology & genetics of tumors of the urinary system and male genital organs. IARC Press, Lyon

22.

Brierly JD, Gospodarowicz M, Wittekind C (2017) TNM classification of malignant tumors, 8th edn. Wiley Blackwell, Oxford

23.

Altman DG, Vergouwe Y, Royston P, Moons KG (2009) Prognosis and prognostic research: validating a prognostic model. BMJ 338:b605CrossRef

24.

Messer J, Shariat SF, Brien JC et al (2011) Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU Int 108:701–705PubMed

25.

Smith AK, Stephenson AJ, Lane BR et al (2011) Inadequacy of biopsy for diagnosis of upper tract urothelial carcinoma: implications for conservative management. Urology 78:82–86CrossRef

26.

Mbeutcha A, Roupret M, Kamat AM et al (2017) Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review. World J Urol 35:337–353CrossRef

Title: Tumour architecture, grade and location remain predictors of non-organ-confined upper tract urothelial carcinoma at time of radical nephroureterectomy: results from a multicenter Norwegian external validation study
Authors: Bjarte Almås
Stein Øverby
Ole J. Halvorsen
Lars A. R. Reisæter
Jørg Assmus
Birgitte Carlsen
Anders Loe
Christian Beisland
Publication date: 01-03-2020
Publisher: Springer Berlin Heidelberg
Keywords: Ureterorenoscopy
Urothelial Cancer
Urothelial Cancer
Published in: World Journal of Urology / Issue 3/2020
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-019-02813-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Tumour architecture, grade and location remain predictors of non-organ-confined upper tract urothelial carcinoma at time of radical nephroureterectomy: results from a multicenter Norwegian external validation study

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2020

The new ISUP 2014/WHO 2016 prostate cancer grade group system: first résumé 5 years after introduction and systemic review of the literature

Photoselective vaporization of the prostate: study outcomes as a function of risk of bias, conflicts of interest, and industrial sponsorship

Prognostic models for predicting overall survival in metastatic castration-resistant prostate cancer: a systematic review

Management of patients with high-risk and advanced prostate cancer in the Middle East: resource-stratified consensus recommendations

Timing of androgen deprivation monotherapy and combined treatments in castration-sensitive and castration-resistant prostate cancer: a narrative review

Microlocalization and clinical significance of stabilin-1+ macrophages in treatment-naïve patients with urothelial carcinoma of the bladder